Truist Financial Has Lowered Expectations for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price target decreased by research analysts at Truist Financial from $59.00 to $50.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price suggests a potential upside of 60.31% from the stock’s current price.

Several other equities research analysts also recently weighed in on ASTH. Macquarie raised shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. BTIG Research upped their target price on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. KeyCorp initiated coverage on Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock. TD Cowen began coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. Finally, Robert W. Baird lifted their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $63.67.

Astrana Health Stock Performance

ASTH stock opened at $31.19 on Monday. Astrana Health has a 1 year low of $29.08 and a 1 year high of $63.20. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of 23.99, a PEG ratio of 1.80 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock’s fifty day moving average is $39.07 and its two-hundred day moving average is $46.97.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. During the same period in the previous year, the business posted $0.47 EPS. On average, research analysts predict that Astrana Health will post 1.16 EPS for the current year.

Hedge Funds Weigh In On Astrana Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASTH. Central Pacific Bank Trust Division purchased a new stake in shares of Astrana Health during the third quarter worth $160,000. SG Americas Securities LLC bought a new position in shares of Astrana Health in the third quarter valued at approximately $680,000. Granite Bay Wealth Management LLC acquired a new stake in shares of Astrana Health in the third quarter worth $290,000. Handelsbanken Fonder AB bought a new stake in shares of Astrana Health during the 3rd quarter worth $492,000. Finally, GAMMA Investing LLC bought a new position in Astrana Health in the 3rd quarter worth $34,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.